Co-Author
This page shows the publications co-authored by Arash Mostaghimi and Sean Singer.
Connection Strength
7.530
-
Association Between Sexual Orientation and Lifetime Prevalence of Skin Cancer in the United States. JAMA Dermatol. 2020 04 01; 156(4):441-445.
Score: 0.914
-
Gender Identity and Lifetime Prevalence of Skin Cancer in the United States. JAMA Dermatol. 2020 04 01; 156(4):458-460.
Score: 0.914
-
State Medicaid Coverage of Dermatologic Procedures and Other Gender-Affirming Services for Transgender Patients in the United States. LGBT Health. 2020 04; 7(3):166-168.
Score: 0.908
-
Skin cancer and skin cancer risk behaviors among sexual and gender minority populations: A systematic review. J Am Acad Dermatol. 2020 Aug; 83(2):511-522.
Score: 0.906
-
Psychiatric Adverse Events in Patients Taking Isotretinoin as Reported in a Food and Drug Administration Database From 1997 to 2017. JAMA Dermatol. 2019 Oct 01; 155(10):1162-1166.
Score: 0.883
-
Conflicts of Interest in Dermatology Patient Advocacy Organizations-Reply. JAMA Dermatol. 2019 Aug 01; 155(8):982-983.
Score: 0.873
-
The ALT-70 cellulitis model maintains predictive value at 24 and 48 hours after presentation. J Am Acad Dermatol. 2019 Dec; 81(6):1252-1256.
Score: 0.851
-
Geographic disparities in access to scalp cooling for the prevention of chemotherapy-induced alopecia in the United States. J Am Acad Dermatol. 2020 Jun 28.
Score: 0.232
-
Contradictory iPledge Requirements Hinder Physician Practice and Patient Care-Reply. JAMA Dermatol. 2020 02 01; 156(2):222-223.
Score: 0.226
-
US Food and Drug Administration Reports of Pregnancy and Pregnancy-Related Adverse Events Associated With Isotretinoin. JAMA Dermatol. 2019 Oct 01; 155(10):1175-1179.
Score: 0.221
-
FDA Reports of Alopecia as an Adverse Event to Isotretinoin. J Cutan Med Surg. 2019 Jul/Aug; 23(4):451-452.
Score: 0.217
-
Prevalence and Disclosure of Potential Conflicts of Interest in Dermatology Patient Advocacy Organizations. JAMA Dermatol. 2019 04 01; 155(4):460-464.
Score: 0.213
-
Association of poor mental health and skin cancer development: a cross-sectional study of adults in the United States. Eur J Cancer Prev. 2020 11; 29(6):520-522.
Score: 0.059
-
Reply to: "Comment on Bullous pemphigoid after anti-PD-1 therapy: a retrospective case-control study evaluating impact on tumor response and survival outcomes". J Am Acad Dermatol. 2020 May 14.
Score: 0.058
-
Bullous pemphigoid after anti-PD-1 therapy: a retrospective case-control study evaluating impact on tumor response and survival outcomes. J Am Acad Dermatol. 2020 Jan 10.
Score: 0.056
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.